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Abstract
Background: Rabies is a major public-health problem in developing countries such as China. Although the recent re-emergence
of human rabies in China was noted in several epidemiological studies, little attention was paid to the reasons behind this
phenomenon paralleling the findings of the previous reports. The purpose of this study is thus first to characterize the current
trends of human rabies in China from 1990 to 2007, and then to define better recommendations for improving the post-
exposure prophylaxis (PEP) schedules delivered to rabies patients.
Methods: The most updated epidemiological data for 22527 human rabies cases from January 1990 to July 2007, retrieved from
the surveillance database of reportable diseases managed by the Ministry of Health of China, were analysed. To investigate the
efficiency for the post-exposure treatment of rabies, the details of 244 rabies patients, including their anti-rabies treatment of
injuries or related incidents, were ascertained in Guangdong provincial jurisdiction. The risk factors to which the patients were
predisposed or the regimens given to 80 patients who received any type of PEP were analysed to identify the reasons for the
PEP failures.
Results: The results from analysis of the large number of human rabies cases showed that rabies in China was largely under
control during the period 1990–1996. However, there has been a large jump in the number of reported rabies cases since 2001
up to a new peak (with an incidence rate of 0.20 per 100000 people) that was reached in 2004, and where the level has remained
until present. Then, we analysed the PEP in 244 rabies cases collected in the Guangdong province in 2003 and 2004, and found
that 67.2% of the patients did not seek medical services or did not receive any PEP. Further analysis of PEP for the 80 rabies
patients who received any type of PEP indicated that almost all of the patients did not receive proper or timely treatment on
the wounds or post-exposure vaccination or rabies immunoglobulins.
Conclusion: While the issue of under-reporting of rabies in previous years may well be a factor in the apparent upwards trend
of human rabies in recent years, the analysis of PEP in the Guangdong province provides evidence that suggests that the failure
to receive PEP was a major factor in the number of human cases in China. Thus, the data underline the need for greatly improved
availability and timely application of high-quality anti-rabies biologicals, both vaccines and immunoglobulins, in the treatment of
human bite victims. Controlling dog rabies through pet vaccination schemes may also play a huge role in reducing the rate of
human exposure. Education of the public, health care staff and veterinarians will also help to change the current situation.
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Background
Rabies is a viral disease that may affect the central nervous
system of any species, but only circulates in mammals [1].
Rabies virus is mainly passed from animal to animal or
animal to human through bites or scratches. In addition
the virus can also be transmitted by the contamination of
wounds. Under very exceptional circumstances, the virus
can cross mucous membranes when the patient inhales
aerosol [2,3]. Rabies epizootics may be divided into two
interrelated cycles, urban and sylvatic. The red fox (Vupes
vulpes) is one of major vectors of the disease and is it res-
ervoir for sylvatic rabies in Eurasia and in parts of Amer-
ica, but it is not the most frequent risk for transmitting
rabies virus directly to humans [3,4]. The more serious
rabies risk to human is imposed by urban rabies. The
domestic dog plays a principal role as a reservoir and
transmitter of urban rabies to humans in China [5].
Humans are also at risk from affected domestic animals or
pets such as cattle and cats at large, or wild animals such
as the raccoon dog in Eurasia and different terrestrial or
flying mammals in the New World [4,6,7]. Moreover,
direct human-to-human transmission has been observed
[8]. There is no effective treatment after the onset of the
associated clinical symptoms. Therefore, the currently rec-
ommended intervention strategy is to remove and neu-
tralize the infectious virus before it enters the nervous
system [2].
According to the official World Health Organization
(WHO) data [9-11], more than 2.5 billion people are at
risk in over 100 countries reporting the disease. Rabies has
the tenth highest mortality of all infectious diseases
worldwide. There are still about 50000 to 60000 human
deaths annually although effective vaccines for post-expo-
sure treatment are available [12]. Developing countries
account for almost all of the reported human deaths, and
most affected are the tropical countries or regions in
Africa, Asia, South America and Oceania. During the
period 1993–2002, the countries of the Americas reported
a decrease of 82% in the number of human cases, with
cases plummeting from 216 in 1993 (mortality rate of
0.03 per 100000 inhabitants) to 39 in 2002 (mortality
rate of less than 0.01 per 100000 inhabitants) [13]. Rabies
is considered as a source of economic loss and, above all,
hampers the movement of animals between different
countries or regions, which has serious implications for
the 'open market' since some countries are currently
rabies free and wish to maintain their disease-free status
[3].
Rabies is a major public-health problem in most of the
developing world [9,14-16]. Prophylactic measures taken
in the past, such as destroying foxes and reducing dog
populations, did not prevent the spread of the rabies,
although recently developed genetically modified rabies
virus vaccines provide an effective method of prevention
of rabies virus infection in dogs, foxes and raccoons [17-
19]. During recent years, most research into the control of
rabies has concentrated on the development of post-expo-
sure prophylaxis (PEP) of rabies [3]. The use of human
rabies immunoglobulin (HRIG) and of equine rabies
immunoglobulin (ERIG) has saved the lives of countless
patients who would have died if treated with vaccine
alone. However, both products are often in short supply
worldwide and virtually unaffordable in developing
countries [20]. Therefore, the high demand for PEP in
Africa and Asia exerts a substantial economic burden, not
only as a result of the high costs of human vaccine and
rabies immunoglobulin (RIG) products, but also because
of considerable indirect (patient) costs associated with
travel and income loss for PEP [21]. Additional economic
losses relate to livestock deaths, which, although poorly
quantified, may be significant, with an estimated annual
incidence of 5 deaths per 100000 cattle, costing US$12.3
million annually in Africa and Asia. The total (direct and
indirect) cost of PEP accounts for 5.8% of annual per cap-
ital gross national income in Africa (US$40 per treatment)
and 3.9% (US$49 per treatment) in Asia [22].
In China, over a 55-year period between 1950 and 2004,
108412 human rabies cases were reported with three
major epidemics occurring during this period [23,24]. The
first epidemic outbreak occurred in the mid-1950s when
cases rose to a peak of about 2000 annually. After a
decline in the 1960s, the number of cases again started to
increase in the early 1970s reaching a peak in 1982, and
then remained at the level of 5000–6000 cases per year
until the end of the decade [25]. Therefore, one of the pur-
poses of this study was to conduct a comprehensive anal-
ysis of the rabies situation in the country using all of the
official data to characterize the current epidemiological
trends of rabies in China from 1990 to 2007. In order to
define better recommendations for improving the PEP
schedules delivered to patients, we also analysed the rea-
sons for the post-exposure treatment failures (or the
absence of PEP), based on the medical records of anti-
rabies treatment of injuries or related incidents for 244
rabies patients, ascertained in Guangdong province of
China in the years of 2003 and 2004.
Methods
Data collection
The epidemiological data for 22527 human rabies cases
from January 1990 to July 2007 were obtained from the
surveillance database of reportable diseases managed by
the Ministry of Health of China. The rabies diagnosis in
humans reported to the national surveillance data bank
was based on the clinical criteria set by the Ministry of
Health of China including the history of animal bite(s),
intense anxiety, nervousness, paralysis in the area of theBMC Infectious Diseases 2008, 8:113 http://www.biomedcentral.com/1471-2334/8/113
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bite, hydrophobia and final death. The history of animal
bite was confirmed by subsequent case epidemiological
surveys from various provincial Centres for Disease Con-
trol and Prevention (CDC) offices. To investigate the effi-
ciency for the post-exposure treatment of rabies, 244
rabies patients with their detailed medical records of anti-
rabies treatment of injuries or related incidents, enrolled
at Guangdong province in the years of 2003 and 2004,
were ascertained from all of the reported rabies cases (441
patients) during the periods. Clinical evaluations were
obtained from all of the participants (or their relatives)
according to the protocols approved by the collectors'
institution review boards of the ethics committees.
Schedule table
The patient's record form adopted for anti-rabies treat-
ment was a standard form designed by the Ministry of
Health of China. At the CDC offices, the form was com-
pleted by the staff who were responsible for clinical eval-
uation and treatment. The patients or their responsible
parties supplied the information entered into the forms.
The variables taken into account for an affected patient
were: (a) the patient's demographic profile: place of resi-
dence, age and sex; (b) exposure characteristics: date of
event, type of exposure (scratch, lick, indirect contact or
bite), site of lesion, number of lesions (single or multi-
ple), type of lesion (superficial or deep); (c) treatment:
time lag between exposure and onset of treatment (delay
in days), procedure adopted (wound care and medica-
tion), type and route of drugs (rabies vaccine, animal
antiserum and/or immunoglobulin), number of doses
prescribed, number of doses administered, type of profes-
sionals who assessed the patient and prescribed or deliv-
ered the treatment.
Data analysis
The distribution and the cumulative number of rabies
cases over all provincial administrative regions of China
for the period 1990–2007 were investigated. The data
were then subjected to statistical analysis, and frequencies
were calculated for the categorical variables. Two epidemi-
ological indices, incidence rate and mortality rate, were
computed to characterize the infectious disease in China.
The incidence rate was the number of new cases of rabies
diagnosed or reported during a defined period of time (for
example, a year), divided by the number of persons in a
stated population in which the cases occurred, expressed
as cases per 100000 per annum in this study. The mortal-
ity rate was calculated by dividing the number of rabies
deaths occurring in the population during the stated
period of time (for example, a year), by the number of per-
sons at risk of dying during the period. The rabies-specific
mortality rate only covered deaths that were a direct result
of the disease and was reported on the basis of 100000
persons in this study. To analyse the risk factors that the
patients were predisposed to or the regimens given to 244
patients, in an attempt to identify the reasons for the PEP
failures or the absence of PEP, a McNemar test, as imple-
mented in a public server [26], was used to test two stud-
ied proportions due to the different exposures or factors
obtained from the 244 patients. This test took into
account the correlation between the two sets of the same
patients, occurring because the patients received alterna-
tive exposure 1 only, alternative exposure 2 only or nei-
ther exposure.
Results
Epidemiological characteristics
The annual incidence rate for rabies is summarized in Fig-
ure 1. The results from analysis of a total of 22527 human
rabies cases from January 1990 to July 2007 showed that
rabies in China was largely under control during the
period 1990–1996, when nationwide rabies vaccination
campaigns were conducted. The data collected showed
that after a decrease in human rabies cases during that
period, the incidence started to rise and a total of 3279
cases were reported in 2006.
In 1996, the number of reported cases dropped to the low-
est frequency (159 cases), in sharp contrast to the figure
for 1990, with 3520 cases reported nationwide. The 1996
yearly incidence rate of rabies in China was 0.013 per
100000 inhabitants. During 1996–1999, the yearly inci-
dence rate of rabies, although increasing slightly, was rel-
atively stable, but later the figures jumped dramatically. In
2005, 2571 cases of rabies were documented. Since the
start of the new millennium, the incidence rates of human
rabies increased from 0.0889 per 100000 inhabitants in
2002 (1159 cases) to 0.1511 (2037 cases) in 2003; this
incremental trend continued into 2004 (2651 cases),
2005 (2571 cases) and 2006 (3279 cases). The data for
2007 are incomplete, but between January and July there
were 1740 human rabies cases reported, an increase of
28.98% compared with the same period in 2006 (1349
cases).
The incidence of human rabies, however, is not distrib-
uted evenly in the vast country of China. Figure 2 shows
the geographic distributions in two recent years (Figure 2A
for 2003 and Figure 2B for 2005). The highest prevalence
in both years was registered in the southwestern and
southern territories of China. Hundreds of rabies cases
were identified in the regions including Guizhou,
Guangxi, Hunan and Guangdong provinces. In 2003,
there were no reported cases in the north, northeast or
west of China. However, in 2005, human rabies expanded
to much wider regions, even the far-west region (Xinjiang
provincial jurisdiction; Figure 2B). There were no reported
cases in Inner Mongolia, Heilongjiang, Qinghai, Ningxia,
Tibet, Gansu or Liaoning provinces. In either year inBMC Infectious Diseases 2008, 8:113 http://www.biomedcentral.com/1471-2334/8/113
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almost all provinces of China, the mortality rate (data not
shown) was identical or similar to the incidence rate as,
once clinical signs of rabies appeared, the disease was
essentially 100% fatal.
We had a particular interest in four neighbouring, highly
populated provinces (Guangdong, Guangxi, Hubei and
Hunan) in southern/central China, because the incidence
rates were relatively higher, and the corresponding CDCs
had more clinical details for the human rabies patients. A
comparison between the provinces, shown in Figure 3,
demonstrated that Hubei had the highest average number
of rabies cases in 1990–1995 (for example, 311 cases in
1990); the number of cases decreased or remained stable
until 2000, but there was another large increase from
2001. The same or similar temporal trend of rabies was
also observed in the other three provinces, which may
well capture the unique epidemiological profiles of the
tropical or subtropical southern regions in recent years.
These data indicate that while China was largely free of
human rabies in the final years of the last century, a wor-
rying trend has started to emerge.
Post-exposure treatment (PEP)
According to the current WHO guidelines, we divided
rabies post-exposures into three categories (see Additional
file 1 for details). Exposure category I describes the lightest
degree of exposure to infection, without any skin injury,
while category III describes the most serious situations
where single or multiple transdermal bites or scratches
occurred that required immediate wound treatment and
anti-rabies vaccines.
China banned nervous tissue vaccines (NTVs) in 1981, so
different provinces adopted slightly different options for
rabies vaccine products. For example, Guangdong provin-
cial CDC recommended using the following products:
purified Vero cell rabies vaccine (PVRV, Aventis Pasteur,
Lyon, France), purified chick embryo cell vaccine (PCEV,
ChengDa Biologicals, Shengyang, China) and hamster
kidney cell vaccine (PHKCV, Lanzhou Institute of Biolog-
ical Products, Lanzhou, China). Nevertheless, there are
substantial numbers of vaccine products produced by
small companies or institutes in China, thus lacking suit-
able quality and efficacy control. These low-quality vac-
cine products not only increased the difficulties in
controlling and preventing rabies, but also complicated
the public health programmes in other Asian countries
that imported these products. The standard post-exposure
vaccination schedule was the 'Essen' 5-dose intramuscular
regimen on days of 0, 3, 7, 14 and 28. However, five pre-
exposure or post-exposure schedules are currently used in
China (see Additional file 2 for details).
The temporal trends of human rabies in China, from 1990 to 2006 Figure 1
The temporal trends of human rabies in China, from 1990 to 2006.
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Geographic distribution of human rabies in China Figure 2
Geographic distribution of human rabies in China. Incidence rates in (A) 2003 and (B) 2005 per million people with the 
scale: blank, none; blue, 0–0.2; green, 0.2–0.4; red, > 0.4.
A: 2003
B: 2005BMC Infectious Diseases 2008, 8:113 http://www.biomedcentral.com/1471-2334/8/113
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Analysis of post-exposure treatment failures
We analysed the PEP in the rabies cases in Guangdong
province. This could be a suggestion that the lack of ade-
quate PEP is one of the major problems in the current sit-
uation in China, since Guangdong has one of the highest
incidence rates and also has the best information availa-
ble. There were 197 and 244 human rabies cases reported
in 2003 and 2004, respectively. However, only 244 cases
(130 cases in 2003 and 114 cases in 2004) had sufficient
information (demographic and clinical data) to be suita-
ble for the analysis of post-exposure treatment failures or
absence of PEP. To look at the information for the virus
transmitters, we found that most of the 244 human rabies
cases were infected by dogs (209 cases, 85.7%), followed
by cats (9 cases, 3.7%) and rats (6 cases, 2.5%). In detail,
the dogs could be classified as owned by the patients
themselves (101/209, 48.3%), dogs belonging to some
one else in the neighbourhood (38/209, 18.2%), stray
dogs (38/209, 18.2%) and others (32/109, 15.3%). A
McNemar test revealed that virus transmission by dogs
was highly significant (P < 0.01) compared with other ani-
mals. The frequency of incidents was higher for male
patients and most patients were under 20 years old. Direct
or indirect contact accounted for 96.47% of the types of
exposure and the remaining 3.53% were via unknown
means. Per the degrees of exposure described, categories I-
III accounted for 33.6%, 38.9% and 22.5% of the patients,
and the remaining 5% were not classified due to the
incomplete data. The time lags between the incidents and
the presentation of patients for anti-rabies assessment
ranged from 0 to 3 days in most cases. According to the
available data on the lesion sites for 109 patients in 2004,
most often affected were the arms (31/109, 28.4%), legs
(31/109, 28.4%) or fingers (24/109, 22.0%); see Addi-
tional file 3 for a graphical illustration. Using a McNemar
test (P  < 0.01), we found that single injuries (82/109,
75.2%) were more frequent than multiple injuries (18/
109, 16.5%).
A comparison of the incidence of rabies between four southern provinces (Guangdong, Guangxi, Hubei and Hunan) of China Figure 3
A comparison of the incidence of rabies between four southern provinces (Guangdong, Guangxi, Hubei and 
Hunan) of China. Note that the data for 1997–1999 for Guangdong were not available.
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Among the 244 cases with informative medical records,
67.2% (164/244) did not seek any medical service and the
remaining 32.8% (80/244) received PEP. Table 1 shows
the analysis of post-exposure treatment failures per the
risk factors that patients were predisposed to or regimens
given to the 80 patients who received any type of PEP.
Among the 80 patients, 62.5% (50/80) only had their
wounds washed with water by themselves, 37.5% (30/80)
went to hospitals or local CDCs to have proper treatment
of their wounds (washed with soap water or clean water
for at least 15 minutes, and then embrocated with 2–3%
tincture of iodine or 75% alcohol), 45% (36/80) of
patients did not receive any rabies vaccine or passive
immunization and 47.5% (38/80) of patients received
between one and four shots of rabies vaccine, but none of
passive immunization. Of the 80 cases who received PEP,
only 7.5% (6/80) of patients received a full regime. These
six patients had a category III exposure, of which five had
a bite on the head and neck and one case had multiple
bites. They all received the following treatment within 24
hours of the bites: (1) wounds were washed with soap and
water or clean water for at least 15 minutes; (2) wounds
were then embrocated with 2–3% tincture of iodine or
75% alcohol; (3) animal antiserum (40 IU/kg) or human
immunoglobulin (20 IU/kg) was injected into the area
surrounding the wounds; (4) one full ampoule of rabies
vaccine was administered IM on days 0, 3, 7, 14 and 28.
Five cases received PCEV or PHKCV made in China, and
one received PVRV imported from France. Nevertheless,
all six patients finally died from the rabies infection. After
careful scrutiny of the six cases, the reduced quality of the
vaccine due improper storage by the patients themselves
after the first shot and lower doses might have contributed
to the failures, while the lesion site (on the head and neck
or multiple bites) may well be a factor causing the failures
in the six cases. In short, according to the current WHO
guidelines, none of 244 cases reported received both ade-
quate and sufficient post-exposure treatment.
Discussion
In China, human rabies was largely under control in the
period 1990–1996, owing to nationwide rabies vaccina-
tion programmes. Since the vast majority of cases were a
result of canine rabies, an extensive dog vaccination pro-
gramme was initiated in 1987 [27]. From 1990 to 1996,
canine rabies decreased by 95.5%, while the GDP (gross
domestic product) increased considerably in the same
period. During the period 1996–1999, the yearly trend for
human rabies was relatively stable, but the number of
human rabies cases jumped dramatically since the start of
the new millennium. Overall, our data implicate that
while China was largely free of human rabies in the final
years of the last millennium, the recent increase in inci-
dence has been high enough to trigger a warning sign for
control and prevention.
However, the data ascertained at various CDCs may not
well capture the real epidemiological scenarios for human
rabies in China. For example, since the SARS (severe acute
respiratory syndrome) epidemic of 2003, the Chinese
government has set up a systematic and nationwide sur-
veillance network for zoonotic diseases. Increased surveil-
lance together with increased dog or other pet
populations may be the principal factors explaining the
increasing number of cases of human rabies reported in
China in the recent years [27]. The same issues for obtain-
ing unbiased estimates for the epidemiological indices of
rabies (incidence or mortality rates) were noted by Tor-
rence et al. [28] in similar studies, and by Brazuna et al.
[29] in a study of Brazilians. It should be noted that this
bias is not unique to the data ascertained at various CDCs,
but is instead common to many medical experiments (for
example, hospital-based studies) where random sampling
is not a feasible (often less-efficient) strategy for data col-
lection. However, there is a list of factors influencing pre-
cise and accurate estimation of human rabies parameters.
These include the following factors: (1) many people,
especially in remote areas, do not have easy access to a
public health service; (2) there was a dearth of knowledge
about rabies in the general public and among health
workers; (3) there was insufficient diagnostic capability
and facilities in the country so that some case reports may
not be able to be sent to the surveillance database at the
Ministry of Health of China. Despite these limitations, the
results clearly demonstrated that rabies constituted a real
public problem in China and its control should be a top
priority.
Our data also indicate that most incidents occurred in the
southwestern and southern territories of China, and most
frequently in the highly populated areas. For example, in
2005, rabies was routinely identified in Guizhou (481
cases), Guangxi (480 cases), Hunan (379 cases) and
Guangdong (306 cases) provinces. The four rabies-
endemic provinces lacked strictly enforced measures to
eliminate dog rabies or an ample supply of modern cell
culture rabies vaccines for humans. It was also interesting
to note that most of patients were young in the range of
0–20 years old and the major victims of rabies were chil-
Table 1: Analysis of post-exposure treatment failures per the risk 
factors predisposed to or regimens given to 80 patients who 
received any type of PEP, collected in Guangdong province
Factor Known cases
Multiple wounds and/or bite on head and neck 55 (68.8%)
Insufficient wound treatment 50 (62.5%)
Delay of two or more days 34 (42.5%)
No rabies immunoglobulin given 73 (91.3%)
No rabies vaccines given 74 (92.5%)BMC Infectious Diseases 2008, 8:113 http://www.biomedcentral.com/1471-2334/8/113
Page 8 of 10
(page number not for citation purposes)
dren less than 16 years old, perhaps as they are bitten by
dogs more frequently than adults. When attacked by dogs,
the lesions were often on the child's head and neck, thus,
not surprisingly, this lesion site was associated with the
highest risk for developing rabies [21,30,31].
In our study of the 244 human rabies cases in Guangdong
province, 67.2% of the patients did not seek medical serv-
ices or did not receive any PEP. The time lag between the
incidents and the presentation of patients for anti-rabies
assessment ranged from 0 to 3 days in most cases. Up to
62.5% of the patients did not receive proper treatment of
the wounds, 92.5% did not receive adequate post-expo-
sure vaccination and 91.25% did not receive any anti-
rabies immunoglobulin. These results suggest that the
population investigated may not be aware of the risks of
rabies transmission, as revealed previously [23]. This fact
could be a significant issue for public health based on the
large number of failures for human PEP that have
occurred recently in China. During the study, we found
that education/information regarding rabies can only be
obtained from the public boards at municipal or district
CDCs in Guangdong province. We found few such public
information boards or web pages at police departments
(stations), community hospitals or offices, in villages and
so on. In December 2007, we conducted a survey among
270 students of preventive medicine at our institute. We
observed that the students had a basic knowledge of
rabies, but had some misunderstandings. Among the stu-
dents, 92.2% could answer questions regarding PEP
regimes correctly. However, only 47.4% knew that wash-
ing the wounds can remove the virus residue on the
lesions, and the percentage of students answering this cor-
rectly for students in grades 2–5 was 42.6%, 32.0%,
60.0% and 70.4%, respectively. Only 58.9% of the stu-
dents knew the pre-exposure administration regime for
rabies vaccine. However, 71.5% of the students knew the
post-exposure administration regime for rabies vaccine
and 57.8% knew the immunization sites for rabies vac-
cine.
In rabies-infested developing countries, modern cell cul-
ture vaccines are too costly for the poorly developed
remote regions, so dangerous NTVs are still used [32-34].
Over the last 4 years in China, of the more than 2000 peo-
ple yearly who died of rabies, only about one-third
received rabies vaccinations. This figure was even lower
(7.5%) in Guangdong province, as estimated in this
study. In most cases of vaccine failures, patients con-
tracted the disease before the full PEP regimen was com-
pleted [24]. In addition, there was a critical shortage of
human and purified equine rabies immunoglobulin in
these regions, which are essential in the treatment of
severe exposure. Although the costs of modern vaccines
are decreasing, the current price of a full-dose intramuscu-
lar vaccine treatment is somewhat beyond what an aver-
age family in developing countries can afford [35,36]. For
example, the average annual income per capita in Guang-
dong province is US$3000 and the rabies vaccine costs
US$12.5–45.0, taking up 0.42–1.51% of the average
annual income per capita. This figure would be much
higher we consider the fact that about 60–70% cases were
from poor rural areas or habos. Furthermore, the supply
of modern and safe vaccines for many provinces are
grossly inadequate, whereas the demand for affordable
and safe human post-exposure treatment is increasing in
these provincial regions [23,24]. Consequently, only anti-
rabies vaccines and human immunoglobulin are availa-
ble, and provide feasible solutions for efficiently control-
ling rabies in the majority of municipalities of China or
other developing countries [16,37-39].
Finally, a mass vaccination dog campaign for the control
and elimination of rabies transmitted by dogs is very
important. China has not implemented enforced immu-
nization for dogs. Rabies vaccine was provided at the cost
of the owners, and the cost was expensive, from tens to
hundreds of Chinese Yuan. Dogs were registered at local
police departments, while animal rabies vaccines were
administrated by veterinarians, thus there was a lack of
good communication or effective strategies for rabies con-
trol in dogs. It appears that the increase in canine rabies,
increase in the dog population and decrease in the vaccine
coverage of dogs may have contributed to the apparent
upwards trend in human rabies in recent years in China.
Based on Chinese CDCs' surveillance of dog rabies in
some typical affected areas, the positive rate was 3.9% (4/
102, Guangxi province) in 1999, 9.1% (76/838, Hunan,
Henan, Guangxi, Guizhou and Jiangsu provinces) in 2004
and 5.9% (5/85, Guizhou province) in 2005. This pattern
is fairly consistent with human rabies. Nevertheless, the
methods of control undertaken by Latin American coun-
tries might provide promising ways for China to develop
a more effective programme for controlling human rabies
transmitted by dogs. With the support from the Pan Amer-
ican Health Organization, several measures such as the
decentralization of health units with PEP available, dog
vaccination coverage and dog rabies surveillance have
been successful in achieving the goal of eliminating
human rabies transmitted by dogs [40].
Conclusion
This large-scale epidemiological study has demonstrated
that human rabies was largely under control in China
between the years of 1990 and 1996, via the national
rabies vaccination programmes. However, the number of
reported rabies cases has started to increase since then.
From 2001, this figure increased significantly to a new
peak that was reached in 2004, where it has remained.
Based on the investigation of 244 human rabies cases col-BMC Infectious Diseases 2008, 8:113 http://www.biomedcentral.com/1471-2334/8/113
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lected in Guangdong province in 2003 and 2004, 67.2%
of patients did not seek medical services or did not receive
any PEP. Further analysis of the post-exposure treatment
failures for 80 rabies patients who received any type of
PEP indicated that the majority of patients, if not all, did
not receive proper and timely treatments on the wounds
or post-exposure vaccination. The study implicated that:
(1) the incidence of human rabies, which China was
largely free from in the final years of the last millennium,
is now increasing which should be a warning sign for con-
trol and prevention; (2) there is a need to improve the cur-
rent rabies control programme in order to reduce non-
compliance rates and to decrease the occurrence of flaws
in the surveillance programme and in the provision of
health care. Given the findings of the study, we view the
implementation of the following measures as appropriate
[9-12,41,42]: (a) continuing supervision of the current
human rabies control programme, in order to reduce both
non-compliance rates and the occurrence of flaws in
health-care provision; (b) improving the interactions
between professionals from the divisions of the municipal
health-care network and teams of national programmes;
(c) increase rabies awareness among Chinese health
authorities and policymakers, improve the training of
general practitioners and health care workers, and educate
school children and the general public, which is crucial
for effective rabies control; and (d) urban planning and
development should take ecosystem preservation into
account, in an attempt to balance the interaction between
humans and animals.
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